Investigator Initiated Studies (IIS)
Roche’s IIS program funds independent clinical research using Roche/Genentech medicines to advance science and improve patient care in areas like oncology, neurology, immunology, and rare diseases.
Funder: Roche
Due Dates: Rolling
Funding Amounts: No fixed limits; support may include funding, study drug, materials, and/or information as appropriate.
Summary: Supports independent clinical studies using Roche/Genentech medicines to advance scientific knowledge and improve patient care.
Key Information: Proposals are accepted year-round via the IIS portal; funding is subject to fair market value and scientific merit.
Description
The Investigator Initiated Studies (IIS) program by Roche (Genentech in the US) invites independent researchers, clinicians, and institutions to propose and conduct clinical research using approved or investigational Roche/Genentech medicines. The IIS program aims to advance scientific understanding, generate real-world evidence, and improve patient outcomes by supporting studies that address questions not fully explored in company-sponsored trials. Eligible proposals should align with Roche’s strategic research interests and demonstrate strong scientific merit.
